Translational Nanocarriers for Hemostasis and Targeted Drug Delivery

Dear Colleagues,

The modern haemostasis landscape is dominated by advances in bioactive biomaterials designed for the targeted modulation of haemostatic processes. Through the use of polymeric, ceramic, or composite matrices, these technologies directly intervene in the coagulation cascade, platelet function, and fibrinolysis. The integration of transport systems, such as nanocarriers, further enhances therapeutic precision by enabling site-specific targeting and limiting systemic toxicity.

Translational medicine allows us to not only create innovative materials but also develop a system that responds dynamically to the patient's pathophysiological conditions. In fact, it contributes to the development of nanocarriers through identifying biomarkers and/or receptors expressed by both activated platelets and biochemical alterations at the site of trauma; it allows the engineering of nanocarriers to emulate platelet functions (adhesion, activation, and aggregation) as closely as possible. With the translational approach, it is also possible to optimize the therapeutic window, reducing phenomena related to the risk of thrombosis.

This Special Issue will include, but is not limited to, articles on the following:

- Haemostatic biomaterials;
- Polymeric nanocarriers;
- Lipid nanocarriers;
- Mesoporous silica nanoparticles;
- Nanosponge;
- Hydrogels and nanohydrogels.

I look forward to receiving contributions.

Dr. Federica Curcio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Translational Medicine is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.